cancer pain epidemiology forecast

DelveInsight’s ‘Cancer Pain  Overview - Epidemiology Forecast–2034’ report delivers an in-depth understanding of the cancer pain  historical and forecasted epidemiology as well as the cancer pain epidemiology trends in the United States, EU4 (Germany, France, Italy, Spain) and the UK, and Japan.

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the UK
• Japan

Study Period: 2021-2034

Cancer Pain Understanding

Cancer Pain Overview

The International Association for the study of pain defines pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.” Worldwide, many people are affected by cancer, and the prevalence is rising. Pain is the most typical symptom of cancer at diagnosis and rises in prevalence throughout and beyond cancer treatment and continues to be a major source of suffering in advanced cancer with adverse effects on patients’ life quality and caregiver distress. Cancer pain is a complex biologic phenomenon that is poorly understood or classified. No specific and widely acceptable taxonomy of cancer pain exists. In any given patient, different mechanisms can be responsible for the pain.

Continued in the report…

Etiology and Types of Cancer Pain

Generally, in cancer, the pain is caused by the primary tumor, metastatic disease, or cancer-related treatments; however, a primary cause of the pain cannot always be identified. Most cancer pain is caused by the tumor pressing on bones, nerves, or other organs in the body. Classifications based on the pain duration are acute pain, chronic pain, breakthrough pain, and refractory pain.

Acute pain is due to damage caused by an injury and usually lasts <3–6 months. For example, having an operation can cause acute pain. The pain goes when the wound heals; in the meantime, painkillers will usually keep it under control.

Chronic pain lasts >3–6 months and is persistent due to nerve changes. Nerve changes may be due to cancer pressing on nerves or chemicals produced by a tumor. Nerve changes due to cancer treatment can also cause it. Chronic pain continues long after the injury or treatment is over, can range from mild to severe, and can always be there. Sometimes pain can come on quickly, for example, when changing a dressing or moving around; this type is incident pain.

Continued in the report…

Cancer Pain Epidemiology Perspective by DelveInsight

The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Cases of Cancer Pain, Etiology-specific Cases of Cancer Pain, Incident Cases of Chemotherapy-Induced Peripheral Neuropathy, Severity-specific Cases of Cancer Pain, Pathophysiology-specific Cases of Cancer Pain, Temporal Variation-specific Cases of Cancer Pain, Incident Cases of Breakthrough Cancer Pain (BTcP) covering the United States, the EU4 (Germany, France, Italy, Spain), UK and Japan from 2021 to 2034.

Cancer Pain Detailed Epidemiology Segmentation

• In 2021, the total incident cases of cancer pain in the US were ~2,321,000 cases, which are anticipated to increase in 2034.
• EU4 and the UK, in 2021, accounted for ~2,278,000 cases of cancer pain, which are anticipated to increase by the year 2034.
• Among the EU4 countries, the highest number of cases of cancer pain were found in Germany, i.e., ~634,000 cases in the year 2021, which are estimated to increase by the year 2034.
• In 2021, the incident cases of breakthrough cancer pain were ~379,000 in France. These cases are expected to increase during the forecast period.

Scope of the Report

• The report covers a descriptive overview of cancer pain, explaining its procedure, types and indications.
• The report provides insight into 7MM historical and forecasted patient pool covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan.
• The report assesses the cancer pain risk and burden.
• The report provides the segmentation of the epidemiology for 7MM by segmented by ‘Total Cases of Cancer Pain, Etiology-specific Cases of Cancer Pain, Incident Cases of Chemotherapy-Induced Peripheral Neuropathy, Severity-specific Cases of Cancer Pain, Pathophysiology-specific Cases of Cancer Pain, Temporal Variation-specific Cases of Cancer Pain, Incident Cases of Breakthrough Cancer Pain (BTcP)’.

Report Highlights

• 10-year forecast of Cancer Pain
• 7MM Coverage
• Total Cases of Cancer Pain
• Etiology-specific Cases of Cancer Pain
• Incident Cases of Chemotherapy-Induced Peripheral Neuropathy
• Severity-specific Cases of Cancer Pain
• Pathophysiology-specific Cases of Cancer Pain
• Temporal Variation-specific Cases of Cancer Pain
• Incident Cases of Breakthrough Cancer Pain (BTcP)

Key Questions Answered

• What are the risk, burdens, and unmet needs of cancer pain?
• What is the historical cancer pain patient pool in the United States, EU4 (Germany, France, Italy, Spain), UK and Japan?
• What would be the forecasted patient pool of cancer pain at the 7MM Coverage level?
• What will be the growth opportunities across the 7MM coverage with respect to the patient population pertaining to cancer pain?
• Out of the countries mentioned above, which country would have the highest cases of cancer pain during the forecast period (2025-2034)?
• At what CAGR the population is expected to grow across the 7MM Coverage during the forecast period (2025-2034)?

Reasons to buy

The cancer pain report will allow the user to -

• Develop business strategies by understanding the trends, shaping and driving the 7MM cancer pain epidemiology.
• The cancer pain epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The cancer pain epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.